{"title":"네이버 금융 ─ 뉴스 ─ 많이 본 뉴스","url":"https://finance.naver.com/news/news_list.naver?mode=RANK","favicon":"https://finance.naver.com/news/favicon.ico","elements":[{"title":"‘오미크론 쇼크’ 亞증시 줄줄이 하락","contents":"동아일보","link":"https://finance.naver.com/news/news_read.naver?article_id=0003396631&office_id=020&mode=RANK&typ=0","retrieved":1638241320000},{"title":"급락했던 비트코인, 3% 넘게 반등","contents":"조선일보","link":"https://finance.naver.com/news/news_read.naver?article_id=0003656299&office_id=023&mode=RANK&typ=0","retrieved":1638241500000},{"title":"코스피 장중 하락 전환 2900선 무너져…'오미크론 변동성 장세..","contents":"뉴스1","link":"https://finance.naver.com/news/news_read.naver?article_id=0005754944&office_id=421&mode=RANK&typ=0","retrieved":1638272460000},{"title":"[속보]바이든 \"봉쇄 논의 안해\"…뉴욕증시 일제히 반등","contents":"이데일리","link":"https://finance.naver.com/news/news_read.naver?article_id=0005096570&office_id=018&mode=RANK&typ=0","retrieved":1638252120000},{"title":"지루한 박스피, 지금이 배당주 투자 적기 [이종우 증시 맥짚기]","contents":"이코노미스트","link":"https://finance.naver.com/news/news_read.naver?article_id=0000019243&office_id=243&mode=RANK&typ=0","retrieved":1638252060000},{"title":"코스피, 1%가량 하락해 2900선 '붕괴'…천스닥도 깨졌다","contents":"한국경제","link":"https://finance.naver.com/news/news_read.naver?article_id=0004634576&office_id=015&mode=RANK&typ=0","retrieved":1638273240000},{"title":"코스피, 국내 오미크론 확진자 소식에 1% 하락···2,870선..","contents":"서울경제","link":"https://finance.naver.com/news/news_read.naver?article_id=0003991121&office_id=011&mode=RANK&typ=0","retrieved":1638272520000},{"title":"전 상장사에 '핵심감사제' 도입, 얼마나 지켜졌나 보니","contents":"머니투데이","link":"https://finance.naver.com/news/news_read.naver?article_id=0004677006&office_id=008&mode=RANK&typ=0","retrieved":1638230400000},{"title":"금융투자협회, 알투플러스 서포터즈 발대식 개최","contents":"아이뉴스24","link":"https://finance.naver.com/news/news_read.naver?article_id=0000639452&office_id=031&mode=RANK&typ=0","retrieved":1638273480000},{"title":"[고수칼럼] 국민연금 100% 활용 방법은?","contents":"머니S","link":"https://finance.naver.com/news/news_read.naver?article_id=0000759449&office_id=417&mode=RANK&typ=0","retrieved":1638256200000},{"title":"오미크론발 유가급락에 원유 ETF·ETN 상품 줄하락","contents":"매일경제","link":"https://finance.naver.com/news/news_read.naver?article_id=0004886414&office_id=009&mode=RANK&typ=0","retrieved":1638273480000},{"title":"[주린이의 공모주] \"주가 떨어지면 환매가능\"…툴젠, 코스닥 이..","contents":"아이뉴스24","link":"https://finance.naver.com/news/news_read.naver?article_id=0000639326&office_id=031&mode=RANK&typ=0","retrieved":1638252060000},{"title":"\"오미크론 즉각 확인 어려워\"···진단키트주, 일제히 하락세","contents":"서울경제","link":"https://finance.naver.com/news/news_read.naver?article_id=0003991125&office_id=011&mode=RANK&typ=0","retrieved":1638230400000},{"title":"외부감사인이 가장 면밀히 보는 감사 항목은?...\"수익인식과 자..","contents":"아시아경제","link":"https://finance.naver.com/news/news_read.naver?article_id=0005007737&office_id=277&mode=RANK&typ=0","retrieved":1638230400000},{"title":"[마켓인]‘이슈株냐 실적株냐’...증시 입성 투자社에 관심 집중","contents":"이데일리","link":"https://finance.naver.com/news/news_read.naver?article_id=0005096550&office_id=018&mode=RANK&typ=0","retrieved":1638235260000},{"title":"[뉴욕증시]'S&P 1.3% 반등' 한숨 돌렸지만…변이 리스크 ..","contents":"이데일리","link":"https://finance.naver.com/news/news_read.naver?article_id=0005096583&office_id=018&mode=RANK&typ=0","retrieved":1638256080000},{"title":"외인 매도에 코스닥 하락 전환…다시 1000선 밑으로","contents":"이데일리","link":"https://finance.naver.com/news/news_read.naver?article_id=0005096869&office_id=018&mode=RANK&typ=0","retrieved":1638272640000},{"title":"3분기 은행 부실채권 11조9000억원…전분기比 2%↓","contents":"데일리안","link":"https://finance.naver.com/news/news_read.naver?article_id=0002552639&office_id=119&mode=RANK&typ=0","retrieved":1638252060000},{"title":"IBK투자증권, 'AA급' 증권사로 도약… \"지배력 확대·수익성..","contents":"머니S","link":"https://finance.naver.com/news/news_read.naver?article_id=0000759421&office_id=417&mode=RANK&typ=0","retrieved":1638251220000},{"title":"[속보] 美 백신업체 모더나 또 11.80% 폭등","contents":"뉴스1","link":"https://finance.naver.com/news/news_read.naver?article_id=0005754080&office_id=421&mode=RANK&typ=0","retrieved":1638252060000},{"title":"툴젠, 바이오 투심 악화에 희망 범위보다 낮은 7만원 공모가 확..","contents":"이데일리","link":"https://finance.naver.com/news/news_read.naver?article_id=0005096870&office_id=018&mode=RANK&typ=0","retrieved":1638272820000},{"title":"상장사 핵심감사사항 개수 감소…자산규모 클수록 KAM 많아","contents":"이데일리","link":"https://finance.naver.com/news/news_read.naver?article_id=0005096883&office_id=018&mode=RANK&typ=0","retrieved":1638230520000},{"title":"'오미크론'에 놀란 동학개미, 매도세 이어지나","contents":"뉴시스","link":"https://finance.naver.com/news/news_read.naver?article_id=0010860852&office_id=003&mode=RANK&typ=0","retrieved":1638252000000},{"title":"변동성에 강한 '리츠', 오미크론에도 인기 이어간다","contents":"이데일리","link":"https://finance.naver.com/news/news_read.naver?article_id=0005096549&office_id=018&mode=RANK&typ=0","retrieved":1638231611084},{"title":"자산운용사, 3분기 해외 주식투자 전년比 21%↑… 증권사는 감..","contents":"머니S","link":"https://finance.naver.com/news/news_read.naver?article_id=0000759413&office_id=417&mode=RANK&typ=0","retrieved":1638250140000}]}